InClinica CEO Speaks at The Symposium on Clinical Pain Trials in Europe

Press Releases

InClinica CEO Speaks at The Symposium on Clinical Pain Trials in Europe

James Nolan to provide industry perspective on issues facing clinical trials

PHILADELPHIA (OCTOBER 25, 2017)InClinica, Inc., a global, clinical CRO, announced that CEO James Nolan presented a special lecture titled “Clinical Pain Trials: Industry Perspective” at The Symposium on Clinical Pain Trials in Europe on Wednesday, October 25 in London, United Kingdom.

Nolan’s lecture addressed the key issues facing clinical pain trials in Europe. He also covered the approaches companies need to succeed in the industry.

“Today, clinical trials face a major recruitment crisis, and clinical pain trials are no exception,” said Nolan. “New companies are developing novel targets for pain, entering clinical trials, and recruiting, but the patient population isn’t growing at the same speed. With more and more companies competing for the same pool of patients, these companies are fighting an uphill battle to complete their trials.”

The Symposium for Clinical Pain Trials in Europe focuses on increasing the accuracy with which clinical trials measure chronic pain and disability—while at the same time examining how to measure meaningful improvement. The Symposium brings together researchers, clinicians, industry professionals and other related experts to look at ways of improving the situation by developing better ideas and best practices in clinical trials on pain. For more information, visit:

About InClinica

InClinica is a global clinical contract research organization founded in 2016 after the acquisition of an existing global CRO. With a senior management team that brings more than 100 combined years of experience, InClinica works across all phases of the clinical research process and has a particular strength in first in man and phase 2 studies. InClinica is headquartered in Philadelphia with other locations in Israel, Malaysia/Singapore., the U.K., and throughout Europe.